Refine by
Respiratory Syndrome Articles & Analysis: Older
38 news found
Viral Vaccine Manufacturing to control pandemics: The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome–coronavirus 2 (SARS-CoV-2) has created a global public health crisis. ...
ByNuvonis
Egan was one of five scientists that founded ONY Biotech, then ONY, Inc., in 1985 in hopes of developing a lung surfactant to treat premature infants born with respiratory distress syndrome, known as RDS. A few years later, in 1988, Dr. ...
Prior studies indicate that high levels of IL-6 serve as an early indication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-induced hyperinflammation, disease severity, and multiorgan ...
It also showed broad-spectrum antiviral activities, not only for SARS-CoV-2 and its variants, but also for other types of coronaviruses that cause diseases including severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). ...
Longeveron is currently sponsoring Phase 1 and 2 clinical trials in the following indications: Aging Frailty, Alzheimer’s disease, the Metabolic Syndrome, Acute Respiratory Distress Syndrome (ARDS), and hypoplastic left heart syndrome (HLHS). ...
This allows BioCardia to initiate its First-in-Human Phase I/II trial in adult patients recovering from Acute Respiratory Distress Syndrome (ARDS) due to COVID-19, with trial initiation expected in the third quarter of 2022. ...
In addition, his regulatory and regenerative medicine experience will be a tremendous benefit to our Aging Frailty and rare pediatric Hypoplastic Left Heart Syndrome (HLHS) programs.” Dr. Min brings to Longeveron over a decade of pharma and biotech clinical development experience. ...
In addition, we recently completed enrollment in our Phase 1/2 clinical trial for INO-3107, our DNA immunotherapy for the rare disease recurrent respiratory papillomatosis (RRP), which received orphan drug designation from the U.S. ...
In pre-clinical data, TSC has been observed to affect oxygen diffusion to hypoxic tissues and provide a functional benefit in animal models of GBM, acute respiratory distress syndrome/acute lung injury, hemorrhagic shock, and ischemic stroke. ...
ByCervoMed
Longeveron is currently sponsoring Phase 1 and 2 clinical trials in the following indications: Aging Frailty, Alzheimer’s disease, the Metabolic Syndrome, Acute Respiratory Distress Syndrome (ARDS), and hypoplastic left heart syndrome (HLHS). ...
Longeveron is currently sponsoring Phase 1 and 2 clinical trials in the following indications: Aging Frailty, Alzheimer’s disease, the Metabolic Syndrome, Acute Respiratory Distress Syndrome (ARDS), and hypoplastic left heart syndrome (HLHS). ...
Aerogen Pharma, a developer of innovative inhaled treatments for patients in critical care, and Nuance Pharma (“Nuance”), a specialty care focused biopharma with late-stage clinical programs and existing commercial operations, today announce an exclusive agreement to join forces in Greater China to develop a superior, non-invasive approach to treatment of RDS, a life-threatening ...
ByAerogen
NEW YORK, December 17, 2021 – Brooklyn ImmunoTherapeutics, Inc. (Nasdaq: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, today announces that Brooklyn has been added to the ICE Biotechnology Index (NYSE:ICEBIO) following the ...
Vent2Cool improves survival and morbidity outcomes of Post Cardiac Arrest Syndrome by inducing ultra-rapid therapeutic hypothermia, reaching 33°C within minutes versus hours with current hypothermia devices. Orixha’s proprietary Lung Conservative Liquid Ventilation technology, once validated in therapeutic hypothermia, will be developed for other Critical Care ...
(see references below) About INOVIO's DNA Medicines Platform INOVIO has 15 DNA vaccine candidate clinical programs currently in development and focused on HPV-associated diseases, cancer, and infectious diseases, including programs for Middle East Respiratory Syndrome, Lassa Fever and COVID-19 being developed under grants from the Coalition for Epidemic ...
Announced online publication in The Lancet Microbe of the results of a Phase 1 clinical trial of VTP-500, a vaccine candidate in development to prevent Middle East Respiratory Syndrome (MERS). The study, conducted by researchers at The King Abdullah International Medical Research Centre and Oxford University, showed that the vaccine candidate was generally well ...
In a randomized control trial (RCT) published in the journal Shock, the BVA-100 test has shown to reduce ICU mortality by 66% (P=0.03) and reduce ventilator days in patients suffering predominantly from acute respiratory distress syndrome and septic shock. Additionally, the analysis showed 44% of BVA test results led to a change in treatment strategy (P=0.004) ...
(POP BIO) received a $599,981, two-year Phase I Small Business Innovation Research (SBIR) under Award No. 1R43AI165089-01, supported by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to pursue development of a potentially life-saving vaccine technology to address the ongoing pandemic crisis caused by Severe Acute ...
Neurokinin-1 Receptor Positive (NK1R+™) Allogeneic Mesenchymal Cell Therapy (BCDA-03 and 04) BioCardia is working to secure acceptance of Investigational New Drug (IND) applications for Phase I/II trials in ischemic systolic heat failure (BCDA-03) and acute respiratory distress syndrome caused by COVID-19 (BCDA-04) in 2021. The FDA recently provided ...
” Pulthera, a Delaware Incorporated Limited Liability Corporation, was formed for the express purpose of advancing medical solutions for those suffering from respiratory conditions including both acute and chronic forms of COVID-19. ...